Primary effusion lymphoma (PEL) is a fatal malignancy, which typically presents as a lymphomatous effusion that later disseminates. Rapamycin (Rapa), which targets mTOR (mammalian target of Rapa), is currently evaluated as a treatment for PEL, but the recent development of PEL in Rapa-treated posttransplant recipients questions the drug's use in PEL. Here, we used a murine model of PEL effusion that mimics the human disease to investigate the anti-PEL activity of Rapa. We found that Rapa reduces ascites accumulation and extends mouse survival. Initially, Rapa reduced PEL load compared with control mice, but most mice rapidly showed PEL progression. Levels of VEGF, which promotes vascular permeability contributing to effusion formation, were significantly reduced in ascites of Rapa-treated mice compared with controls. Expression of IL-10, the principal autocrine growth factor for PEL, was initially reduced in PEL from Rapa-treated mice but rapidly increased despite treatment. We found that the hypoxic environment of ascites and Rapa cooperate in stimulating IL-10 expression in PEL, which likely contributes to the emergence of drug resistance. These results identify Rapa an effective drug to reduce PEL effusions but illustrate the rapid development of drug resistance, which likely limits the efficacy of Rapa in PEL.
Introduction
Primary effusion lymphoma (PEL) is a highly aggressive lymphoma that characteristically presents as an effusion malignancy in the body cavities of patients with AIDS and occasionally HIV-negative patients.
1,2 Typically, PEL is latently infected with Kaposi's sarcoma herpes virus (KSHV) and is often co-infected with Epstein-Barr virus. 1, 2 In the setting of AIDS, the clinical course of most of these lymphomas is generally aggressive, with a mean survival from diagnosis of 5-7 months despite chemotherapy. 3 Thus, there is a need for improved therapy.
Rapamycin (Rapa) (sirolimus), a macrolide compound approved as an immunosuppressant drug, was shown to exert antineoplastic and antiangiogenic properties. 4, 5 Rapa complexes with the protein FK506-binding protein 12, which functionally inhibits the mammalian target of Rapa (mTOR). 6 mTOR is a regulatory kinase that controls fundamental cell functions, including translation initiation, transcription of stress response genes, ribosomal biogenesis and tRNA synthesis and thus has a central role in cell cycle progression, cell growth and survival. 7 As an inhibitor of mTOR, Rapa inhibits the growth of many cancer cell types in vitro. 8 Stallone et al. 9 reported that switching from cyclosporine-A to Rapa for immunosuppression led to regression of Kaposi's sarcoma (KS) in 15 kidney transplant recipients. As KS and PEL are both KSHV-infected, this observation prompted an evaluation of the potential utility of Rapa in PEL. A recent study reported that Rapa was effective at preventing/delaying development of subcutaneous (s.c.) PEL tumors in mice, leading to the investigational use of Rapa in patients with PEL. 10 More recently, two HIV-1-negative patients developed PEL while receiving Rapa for immunosuppression following kidney transplantation, 11 raising important questions on the safety and efficacy of Rapa in patients with PEL.
To address these questions, we exploited a murine model of PEL that mimics the human disease in being a peritoneal effusion lymphoma that subsequently progresses to form solid tumors. We have found that Rapa induces an initial response but does not eradicate PEL. With continued treatment, environmental stress from the hypoxic environment of the peritoneal cavity initiates a cytokine-mediated escape mechanism leading to disease progression.
Materials and methods

Cell lines
PEL cell lines BC-1 (from Dr Y Chang, University of Pittsburg, PA, USA), BCBL-1 and JSC-1 (from Dr R Yarchoan, NCI, Bethesda, MD, USA), BC-3 (ATCC, Rockville MD, USA) and VG-1 (from Dr David Scadden, Harvard Medical School, Boston, MA, USA) were maintained in RPMI-1640 (GIBCO, Invitrogen, Carlsbard, CA, USA) with 10% heat-inactivated fetal bovine serum (FBS), 1 mM glutamine, at 37 1C in 5% CO 2 . All these cell lines are KSHV-positive; BC-1and JSC-1 cells are also EBV-positive.
Establishment of PEL ascites and tumors
Animal experiments were approved by the NCI Animal Care and Use Committee. Female NOD/SCID mice (6 weeks old) were injected intraperitoneally (i.p.) with BC-1 cells (2 Â 10 7 cells per mouse in 0.2 ml PBS). Groups of mice were either observed untreated or received daily i.p. injections of Rapa (SigmaAldrich, (St Louis, MO, USA) 3 mg/kg, in 0.2 ml diluent) or diluent only, beginning 24-h after PEL inoculation until killing. This Rapa dose was selected based on previous experiments. 4 Animals were euthanized (per protocol) when they developed excessive abdominal distension interfering with movement or causing other distress.
Immunoblotting
Protein extracts for phosphorylated proteins prepared in SDS lysis buffer with protease inhibitor cocktail setIII (Calbiochem, Darmstadt, Germany), 50 mM NaF and 1 mM sodium orthovanadate were resolved in NuPAGE 4-12% Bis-Tris Gel (Invitrogen), transferred to protran membranes (Whatman GmbH, Dassel, Germany). Immunoblotting antibodies for actin, phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, phospho-Akt (Ser473), phospho-Akt (Thr308), Akt, phospho-GSK-3beta (ser9), GSK-3beta, phospho-Src family (Tyr416), non-phospho-Src, phospho-eNOS (ser1177) and eNOS were from Cell Signaling Technologies (Beverly, MA, USA); antibody for LANA was from ABI (Columbia, MD, USA). Monoclonal antibody to RTA was a gift of Dr Kazu (NCI); rabbit polyclonal antibody to vFLIP was a gift of Dr P Chaudhary (Hillman Cancer Center, Pittsburgh, PA, USA). Monoclonal antibodies for vIL-6 (clone 12.1.1) were from our laboratory. 12 Bound secondary antibodies were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). 
Cell proliferation assays
Immunohistochemistry
Tumor sections were deparaffinized, rehydrated, boiled in 10 mM sodium citrate buffer (pH 6.0), cooled, blocked for 1 h at RT (TBS with 10% horse serum (Biosource, Camarillo, CA, USA) and 5% BSA), and incubated overnight (4 1C) with phospho-S6 ribosomal protein (Ser235/236) antibody, rabbit monoclonal S6 ribosomal protein antibody (Cell Signaling Technology). Sections were stained with a goat anti-rabbit biotinylated horseradish peroxidase H-conjugated secondary antibody followed by Avidin DH (VECTASTAIN ABC kit; Vector Laboratories, Burlingame, CA, USA) and by Vector Nova Red substrate for peroxidase (Vector Laboratories). Slides were counterstained with Accustain (Sigma). Images were recorded using Olympus BX41 microscope (Olympus, Center Valley, PA, USA).
Cytokines measurements
Human (h)IL-10, hIL-6, human vascular endothelial growth factor (VEGF) levels were measured using enzyme-linked immunoabsorbent assay (Quantikine, R&D Systems, Minneapolis, MN, USA). The ELISA for detection of vIL-6 was described. 12 Cytokine mRNA levels were measured by real time PCR (Supplementary Information) with primers for hIL-10 and hIL6 from Applied Biosystems (Foster City, CA, USA); primers for vIL-6 were: 5 0 -ACGCGGGGCAAGTTGCCGGAC-3 0 (forward) and 5 0 -TACTTATCGTGGACGTCAGGA-3 0 (reverse). 
Statistical analysis
Results
Rapa inhibits PEL cell proliferation in vitro
We examined whether mTOR is constitutively active in PEL cells by evaluating the phosphorylation status of the mTOR effector S6. We found that S6 is constitutively phosphorylated in the PEL cell lines BC-1, BCBL-1, BC-3, JSC-1 and VG-1, indicative of constitutive mTOR activity in culture. Incubation with 100 nM Rapa for 72 h consistently reduced such phosphorylation ( Figure 1a) . We examined the effect of Rapa on PEL cell growth (bar graph, Figure 1b) . Rapa reduced proliferation in all cell lines tested. VG-1 cells proved the most sensitive (92% reduction with 10 nM Rapa) and BCBL-1 cells proved the least sensitive (26% reduction with 1000 nM Rapa). We evaluated cell viability in these cultures. At 1000 nM, Rapa reduced cell viability to 87.7% in BC-1 cells, but minimally affected viability of all other cell lines (line graph, Figure 1b) . We conclude that Rapa exerts a variable cytostatic effect on PEL cells cultured in vitro, but has little cytotoxicity for these cells.
Rapa inhibits accumulation of PEL ascites
We used a mouse model of PEL to evaluate the anti-tumor effects of Rapa in vivo. PEL cells are inoculated intraperitoneally (i.p.) in NOD/SCID mice resulting in the development of PEL ascites and subsequent formation of solid tumors arising from the parietal and/or visceral mesothelial layer of the peritoneum. This model closely resembles human PEL in displaying a body cavity location, development of lymphomatous ascites and solid body-cavity lymphoma. 1, 2 Pilot experiments showed that PEL cell lines display a varying degree of sensitivity to Rapa treatment in vivo (not shown). We selected the BC-1 cell line for further investigation because it displayed an intermediate sensitivity to Rapa. BC-1 (20 Â 10 6 ) cells were injected i.p. into 15 NOD/SCID mice; three mice were observed untreated, and 12 mice were treated with Rapa (3 mg/kg per mouse per day i.p.) starting 1 day after BC-1 cell injection. By day 15, all control mice developed massive PEL ascites necessitating killing as per protocol. Three Rapa-treated mice with no evidence of disease were also electively killed on day 15. The remaining mice were maintained on Rapa until day 25, when they were electively killed. Rapa significantly (Po0.001) extended the survival of PEL-bearing mice ( Figure 2a) .
We evaluated in all mice (a) ascites volume; (b) PEL load in the ascitic fluid; and (c) presence of tumors at autopsy. All control mice and 10/12 Rapa-treated mice (including 3/3 mice killed on day 15 and 7/9 mice killed on day 25) had ascites, but the mean volume was significantly (Po0.01) reduced in the Rapa-treated mice ( Figure 2b , left panel). The volume of cell-free ascites from the Rapa-treated mice was reduced by 95% in mice killed on day 15 and by 88% in mice killed on day 25 compared with the untreated mice ( Figure 2b , mid panel). We counted PEL cells recovered from all ascites ( Figure 2b , right panel). In the controls, we recovered significantly (P ¼ 0.014) more PEL cells than from the treated animals (65 and 46% reduction on day 15 and 25, respectively). The 2 Rapa-treated mice killed on day 25 without ascites at autopsy had PEL cells in the peritoneal lavage, but fewer cells were recovered than originally injected. The 10 remaining mice had more PEL cells in the ascites than originally injected, evidence that PEL cells had proliferated in vivo despite treatment. PEL cell viability from Rapa-treated mice (75.55 ± 14.7%) was similar to that from control mice (81.0%±3.9). These results indicate that Rapa reduced PEL progression predominantly by reducing fluid accumulation and PEL growth rather than by promoting PEL cell death.
Only 2/12 Rapa-treated mice displayed a solid tumor mass on autopsy, a frequency that was lower than that observed in 17 non parallel control mice injected with BC-1 cells on the same protocol and were killed 18-24 days post PEL injection (2/12 versus 10/17: P ¼ 0.054, Fisher's exact test). The size of the two tumors recovered from the Rapa-treated mice (0.24 and 0.1 cm 3 , mean ¼ 0.17) was smaller than that from the control mice (5.9±5.3 cm 3 ), but the difference was not significant (P ¼ 0.076, exact Wilcoxon's rank sum test). Thus, treatment with Rapa extended the survival of PEL-bearing mice, reduced accumulation of ascites and limited PEL cell growth, but did not clear the mice of PEL.
Rapa blocks mTOR activity in vivo
The downstream effector of mTOR, S6 is constitutively phosphorylated in cultured PEL cells, and Rapa reduces this constitutive phosphorylation in vitro (Figure 1a) . We examined the phosphorylation status of S6 in PEL cells from the mice. S6 protein was phosphorylated to a lower degree in PEL-cell recovered Rapa-treated animals (from day 15 to day 25) compared with controls, providing biochemical evidence of drug activity in vivo (Figure 2c ). By immunohistochemistry, we detected phosphorylated S6 protein in PEL tumors from untreated mice (representative results in Figure 2d ), which was reduced in the only two PEL tumors recovered from treated mice (Figure 2d) . Thus, PEL progression on Rapa occurred in spite of biochemical evidence of persistent drug activity.
Rapa inhibits VEGF secretion and signaling
Malignant ascites results from increased peritoneal capillary permeability, accumulation of plasma exudates in the cavity and reduced drainage by tumor-infiltrated diaphragmatic lymphatic vessels. 13 This process is driven by VEGF. 13 Our group has previously demonstrated that VEGF neutralization prevents accumulation of PEL ascites.
14 As Rapa reduces accumulation of ascites (Figure 2b ), we hypothesized that Rapa reduces VEGF secretion and/or responses to VEGF. We found that Rapa (100 nM) minimally reduces VEGF secretion in BC-1 cells over 72 h culture (results expressed per 10 6 cells, Figure 3a) . Nonetheless, VEGF concentration in the culture supernatants (results expressed per ml) was significantly lower after incubation with Rapa compared with medium only (P ¼ 0.006) due to reduced cell growth. VEGF mRNA levels were minimally affected by Rapa (100 nM; 72 h) in BC-1 cells (Figure 3b ). However, we found that 15 and 25 days Rapa treatment reduced significantly hVEGF secretion by PEL (results expressed per 10 6 cells, Figure 3c ). This reduction was not accompanied by a reduction in the levels of VEGF mRNA (Figure 3d) , and is likely attributable to reduced VEGF translation after prolonged exposure to the drug. Murine (m) VEGF, which was measurable in ascites at concentrations B50-fold lower than those of human (h, tumor-derived) VEGF, was similarly reduced by Rapa treatment (not shown). Thus, treatment of mice with Rapa significantly reduces hVEGF secretion by PEL cells and mVEGF by the host cells.
Rapa exerts anti-angiogenic effects by decreasing VEGF production and blocking Akt/mTOR signaling in VEGF-activated endothelial cells. 15 We tested the effects of Rapa on VEGFinduced signaling by incubating HUVEC with 100 nM Rapa for 72 h and then adding VEGF (100 ng/ml) for 30 min. We found that Rapa reduces VEGF-induced activation of Akt (Ser473 and Thr308), of the Akt/mTOR effectors eNOS, GSK3 b, P70s6K, S6 and of Src (Figure 3e) . We conclude that Rapa can reduce both VEGF production by PEL and VEGF responses by endothelial cells, including eNOS activation, which has been prominently linked to the permeability-promoting effects of Effects of Rapa on PEL P Gasperini and G Tosato VEGF. [16] [17] [18] [19] These results explain the marked reduction of ascites accumulation in Rapa-treated mice bearing PEL.
Effects of Rapa on expression of autocrine growth factors
PEL cells secrete IL-10, IL-6 and vIL-6, [20] [21] [22] and utilize IL-10 and vIL-6, but not IL-6, as autocrine growth factors. 23 Rapa was reported to variably reduce PEL secretion of these proteins; 10, 22 we wished to confirm these results. BC-1 (5 Â 10 5 /ml) cells were cultured (72 h) in medium alone or with 100 nM Rapa; cells were counted and concentrations of IL-10, IL-6 and vIL-6 measured by ELISA in the supernatants. As Rapa reduces BC-1 cell proliferation (Figure 1b) , cytokine levels are expressed relative to cell number (ng/10 6 ). Secretion of IL-10 and IL-6, but not vIL-6, was significantly reduced by Rapa (Figure 4a ). As IL-10 is the most potent autocrine growth factor for PEL, reduced IL-10 secretion likely contributes to reduced PEL cell proliferation with Rapa.
To examine whether Rapa treatment in vivo reduces cytokine secretion, we measured IL-10, IL-6 and vIL-6 concentrations in the cell-free ascites from PEL-bearing mice. As treatment with Rapa reduced PEL cell recovery from ascites, the results are expressed relative to PEL cell number. We found human (h) IL-10 (human-specific ELISA), vIL-6 and hIL-6 (human-specific ELISA) levels to be significantly reduced in the ascites from mice treated with Rapa for 15 days compared with controls ( Figure 4b ). The reduction of vIL-6 and hIL-6 continued to be significant in mice treated with Rapa for 25 days. However, levels of hIL-10 were no longer reduced in the ascites of mice treated for 25 days with Rapa compared with controls. This was surprising because S6 phosphorylation continued to be reduced in PEL cells recovered after 25-days treatment with Rapa (Figure 2c) , indicative of persisting drug activity.
We investigated potential mechanisms underlying the rise in IL-10 secretion by PEL after prolonged treatment with Rapa. Short-term (72 h) exposure to Rapa in vitro minimally altered mRNA levels of IL-10, vIL-6 and IL-6 in PEL cells ( Figure 4c) ; Rapa treatment in vivo for 15 and 25 days did not significantly alter levels of hIL-6 mRNA in PEL cells recovered from ascites. Instead, levels of hIL-10 and vIL-6 mRNAs were significantly increased in PEL cells from mice treated with Rapa for 15 and 25 days (Figure 4d ). vIL-6 mRNA expression doubled on Rapa treatment (15 and 25 days), but this increase was not accompanied by an increase of vIL6 in the ascites (Figure 4b) , possibly due to an effective translational block by Rapa. Levels of hIL-10 mRNA increased two-fold in PEL from 15-day-treated and six-fold from 25-day-treated mice compared with controls ( Figure 4d ). This progressive increase in hIL-10 mRNA levels likely underlies the progressive increase of hIL-10 in the ascites of treated mice. Interestingly, hIL-10 mRNA levels in PEL cells from the peritoneal lavage of the only two mice without ascites after 25-day treatment with Rapa were not increased compared with untreated controls (P40.05), suggesting that increased IL-10 transcription is critical to the survival/ Effects of Rapa on PEL P Gasperini and G Tosato proliferation of PEL cells and may be a surrogate marker of Rapa activity in PEL.
Effects of hypoxia on IL-10 expression and sensitivity to Rapa
To investigate mechanisms for increased IL-10 expression in PEL from mice on prolonged Rapa treatment, we tested whether stress from the hypoxic environment of ascites 24, 25 contributes to increased IL-10 expression in PEL cells. BC-1 cells (5 Â 10 5 / ml) were incubated for 72 h under hypoxic (1% O 2 , 5% CO 2 , 94% N 2 ) or normoxic conditions with or without 100 nM Rapa; levels of IL-10 protein and mRNA were measured in cells and supernatants, respectively. Consistent with the results in Figure 4a , we found that Rapa reduces IL-10 levels in the culture supernatants of BC-1 cells cultured under normoxic conditions (Figure 5a ), but did not decrease IL-10 secretion in BC-1 cells cultured under hypoxic conditions (Figure 5a ). Rapa had similar effects on IL-10 secretion in BC-3 cells (not shown). Rapa did not alter IL-10 mRNA levels in BC-1 cells cultured under normoxic conditions, but promoted a threefold increase in IL-10 mRNA levels in BC-1 cells cultured under hypoxic conditions (Figure 5b ). Rapa did not enhance IL-6 mRNA levels under hypoxic conditions (not shown).
To test whether PEL cells maintain responsiveness to IL-10 on Rapa, BC-1 cells were cultured (72 h) with IL-10 (2-500 pg/ml) with or without Rapa. Without Rapa, BC-1 cells dosedependently proliferated to IL-10, but not IL-6 (not shown), displaying maximal responses at 500 pg/ml (Figure 5c Figures 5a and b show that the hypoxic environment in ascites likely contributes to promote IL-10 expression in PEL cells from mice treated with Rapa, and provide evidence that increased IL-10 expression represents a mechanism for resistance to the cytostatic effects of Rapa.
Rapa does not promote KSHV replication
As KSHV infection is a defining feature of PEL and Rapa inhibits vIL-6 expression in mice treated with the drug (Figure 4b) , we explored more broadly the effects of Rapa on latent, early lytic Effects of Rapa on PEL P Gasperini and G Tosato and late lytic and viral gene expression. We found that Rapa minimally alters mRNA and protein levels of ORF73/LANA, K13/vFLIP, ORFK2/vIL-6, ORK50/RTA and ORF8.1/gpK8.1 (Supplementary Figure 1) . These results demonstrate that Rapa does not promote KSHV replication in PEL cells and that its effects on PEL are unrelated to change in the virus life cycle.
Discussion
Exciting preclinical results showing that Rapa is effective at preventing formation of sc PEL tumors in mice raised the possibility that Rapa may represent a new treatment option for patients with PEL. 10 This enthusiasm was recently tempered by a report describing the development of PEL in two HIV-negative kidney transplant recipients receiving Rapa for immunosuppression. 11 Rapa has been used extensively for immunosuppression to prevent rejection of kidney transplants, and has shown antitumor activity against some tumors, including KS. 5 Both KS and PEL are infected with KSHV in AIDS patients and may co-exist. Here, we selected a murine model of PEL that mimics human PEL in its characteristic location and mode of progression to re-evaluate the effectiveness of Rapa against PEL. We found that Rapa strikingly reduces the accumulation of ascites, delays PEL progression and extends mouse survival, but does not eradicate the disease. Increased IL-10 expression by PEL on extended Rapa treatment contributes to drug resistance.
Analysis of the mechanisms for the striking reduction of ascitic fluid accumulation induced by Rapa revealed that the drug inhibits VEGF secretion by PEL cells and the mouse host, and limits endothelial cell responses to VEGF. It is now clear that VEGF, which promotes vascular permeability, has a critical role in the formation of neoplastic effusions. 26, 27 Here, we found that Rapa not only post-transcriptionally reduces VEGF production but also blocks VEGF-induced signaling in endothelial cells, including activation of P-Akt (ser473) and P-eNOS, which are critical mediators of VEGF-induced vascular permeability. 15, 28 These results are consistent with previous results showing that Rapa inhibits constitutive Akt activation in endothelial cells 15 and that Akt activation is necessary for VEGF permeability, 28 suggesting that Rapa could be effective at reducing the formation of edema and effusions. 15, 29 The current results provide strong evidence that Rapa is an effective inhibitor of body fluids accumulation, which is of potential clinical importance.
Rapa did not eradicate PEL because the drug is not cytotoxic for PEL. After an initial response, PEL cells develop resistance to Rapa. Consistent with previous observations, 10, 30, 31 we found that Rapa post-transcriptionally downregulates PEL production of IL-10, but does not alter IL-10-signaling pathways. As IL-10 is the principal autocrine growth factor for PEL, 23 reduced IL-10 secretion is likely responsible for decreased PEL cell proliferation with Rapa. The resistance to Rapa that rapidly ensues is attributable, at least in part, to increased IL-10 expression on Rapa treatment. We could reproduce in culture key features of this evolution. Rapa was no longer effective at reducing IL-10 secretion by PEL cells exposed to hypoxic stress, a feature of body cavity effusions. 24, 25 Rather, under hypoxic conditions, Rapa promoted IL-10 mRNA expression in PEL cells and enhanced PEL cell survival/proliferation. Thus, we conclude that PEL is only transiently responsive to Rapa because PEL develop an escape mechanism resulting in increased production of IL-10, which promotes PEL cell growth. The only two mice that exhibited a persistent response to Rapa harbored PEL cells that did not show increased IL-10 expression. This suggests that stress factors active in the microenvironment of lymphomatous effusions are important inducers of Rapa resistance in PEL. There is enthusiasm for the development of Rapa and other mTOR inhibitors as cancer therapeutics. Cytotoxicity is generally viewed as essential to effective anticancer therapy, but we find that Rapa is mostly cytostatic for PEL cell lines. It is possible that Rapa is cytotoxic for primary PEL and not for PEL cell lines, which may have developed resistance to the drug through acquired genetic mutations. If primary PEL cells and PEL cell lines respond similarly to Rapa, dual inhibition of mTOR and IL-10 function could be an effective anti-PEL strategy because increased IL-10 expression appears critical to PEL cell lines resistance to Rapa. Importantly, the current results present strong evidence supporting the investigational use of Rapa to reduce fluid accumulation in body cavities affected with PEL and potentially other types of malignant effusions. Effects of Rapa on PEL P Gasperini and G Tosato
